Education
About Us
Working with TipRanks
Follow Us
Zura Bio (ZURA)
NASDAQ:ZURA
ZURA Stock Chart & Stats
$5.50
-$0.21(-8.71%)
At close: 4:00 PM EST
$5.50
-$0.21(-8.71%)
Day’s Range― - ―
52-Week Range$0.97 - $7.44
Previous CloseN/A
Volume136.30K
Average Volume (3M)488.96K
Market Cap
$474.23M
Enterprise Value$271.83M
Total Cash (Recent Filing)$109.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.39
Next Earnings
May 07, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding86,223,305
10 Day Avg. Volume460,186
30 Day Avg. Volume488,963
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-7.60
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.87K
Enterprise Value/Ebitda-3.69
Forecast
1Y Price Target
$18.67Price Target Upside239.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignAnalyst observes the hidradenitis suppurativa Phase 2 study includes measures to limit placebo effects and establishes clear efficacy benchmarks, improving the potential for a persuasive clinical readout.
Dual-target MechanismAnalyst highlights that tibulizumab's bispecific design targets BAFF and IL-17 simultaneously, which could provide broader disease control than single-target drugs and reduce the need for combination therapies.
Unmet Medical NeedAnalyst notes systemic sclerosis and hidradenitis suppurativa lack broadly effective biologic options, so a successful multi-target therapy could address a significant unmet need and support independent commercial development.
Bears Say
Clinical Outcome RiskAnalyst warns that the company's outlook is highly dependent on positive clinical trial results, and negative readouts would materially weaken the investment case.
Financing And Partnership RiskAnalyst indicates that unsuccessful trial results could necessitate external financing or partnership deals on unfavorable terms, potentially diluting shareholders or slowing development progress.
Program Concentration RiskAnalyst cautions that heavy reliance on a single lead program increases exposure to binary trial outcomes and amplifies downside if the program fails.
Zura Bio News
ZURA FAQ
What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was $0.97 and its highest was $7.44 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is $474.23M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s upcoming earnings report date is May 07, 2026 which is in 46 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Mar 19, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.196 by -$0.294.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.18.
How many shares outstanding does Zura Bio have?
Zura Bio has 86,223,305 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.196. Following the earnings report the stock price went down -10.131%.
Which hedge fund is a major shareholder of Zura Bio?
Currently, no hedge funds are holding shares in ZURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zura Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (239.45% Upside)
$18.67 (239.45% Upside)
Blogger Sentiment
Bullish
ZURA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.9%
Last 30 Days ▲ 23.6%
Last 30 Days ▲ 23.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
330.98%
12-Months-Change
Fundamentals
Return on Equity
-83.86%
Trailing 12-Months
Asset Growth
-23.87%
Trailing 12-Months
Company Description
Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
ZURA Stock 12 Month Forecast
Average Price Target
$18.67
▲(239.45% Upside)
Technical Analysis
Ownership Overview
12.82% Insiders
1.59% Mutual Funds
35.62% Other Institutional Investors
49.31% Public Companies and
Individual Investors